Uncategorized

March 17, 2021

N-803, a superagonist of IL-15RαFc, shows promising efficacy in the treatment of bladder carcinoma in situ   

Patients with non-muscle–invasive urothelial carcinoma of the bladder who do not respond to BCG have limited treatment options. N-803 is an immunostimulant protein fusion complex based on mutant IL-15 (IL-15RαFc), […]
April 7, 2020
Selumetinib demonstrates clinical benefit in cases of plexiform neurofibromas

Selumetinib demonstrates clinical benefit in cases of plexiform neurofibromas

Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder characterized by multiple manifestations, including tumors of the nervous system (benign or malignant). In this scenario, […]
April 6, 2020
FDA approves durvalumab for small cell lung cancer in extensive disease

FDA approves durvalumab for small cell lung cancer in extensive disease

On March 27, 2020, the US Food and Drug Administration approved durvalumab in combination with etoposide plus carboplatin or cisplatin for the first-line treatment of patients […]
April 2, 2020
Bladder cancer: combination of durvalumab and tremelimumab does not bring gains in overall survival

Bladder cancer: combination of durvalumab and tremelimumab does not bring gains in overall survival

According to the manufacturer’s recent statement, the combination of durvalumab and tremelimumab did not lead to an increase in overall survival (OS) in patients undergoing treatment […]
March 27, 2020
FDA Approves Combination of Immunotherapy for Advanced Hepatocellular Carcinoma

FDA Approves Combination of Immunotherapy for Advanced Hepatocellular Carcinoma

On March 10, 2020, the Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with hepatocellular […]
January 24, 2020

Study presented at ASCO GI 2020 reveals advances in liquid biopsy

Gastrointestinal tumors are difficult to identify early, sometimes going unnoticed in routine exams. In this context, a study presented at ASCO GI 2020 shows promising results […]
December 19, 2019

Tucatinibe addition increases survival in patients with advanced HER2+ breast cancer

Dr. Hope Rugo, Breast Oncology Director at University of California (USA), attending the 2019 San Antonio Breast Cancer Symposium (SABCS), comments on the positive study for […]
September 25, 2019

ISPOR Latinoamérica analiza los desafíos de los sistemas de salud en América Latina

La gerente ejecutiva de ISPOR, Nancy S. Berg, destacó el compromiso en la organización del evento ISPOR Latinoamérica que se llevó a cabo del 12 al […]
September 25, 2019

La toma de decisiones y la medicina basada en evidencia son fundamentales para ISPOR Latinoamérica

El director de contenidos estratégicos de ISPOR USA, Ramiro Gilardino, habló sobre los aspectos que se analizaron durante el evento ISPOR Latinoamérica para promover la medicina […]